Hexapharmatec identifies new TFEB inducers

June 30, 2026

Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis.

BioWorld Science Inflammatory Patents

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...